North Shore-LIJ, CSHL in cancer partnership

CSHL's Bruce StillmanCSHL director Bruce Stillman.

Cold Spring Harbor Laboratory and North Shore-LIJ announced a joint cancer research and treatment effort that is designed to speed the region’s most-promising research to patients.

The affiliation will better connect researchers at CSHL and North Shore’s Feinstein Institute for Medical Research and provide patients for clinical trials of the latest treatments, linking scieentists with more than 200 oncologists at North Shore-LIJ’s Cancer Institute.

Cold Spring Harbor CEO Bruce Stillman called the paertnership a “transformative affiliation for both institutions.” It also marks North Shore-LIJ’s latest collaboration with other Long Island organizations, after teaming on a new medical school with Hofstra University and expanding research efforts with Stony Brook University and Brookhaven National Lab.

North Shore-LIJ CEO Michael Dowling said the collaboration could change the “approach to cancer research and treatment throughout the New York area” by providing earlier access to treatments.

The partnership is being launched with $120 million, to be used to advance cancer research, develop a clinical cancer research unit at North Shore-LIJ’s Cancer Institute and recruit and train scientists specializing in cancer.

North Shore-LIJ has already invested $175 million in cancer efforts, including $84 million to expand the Cancer Institute headquarters.

North Shore- LIJ currently treats more than 16,000 cancer patients annually.